Summary and Key Points
1. Staging of cancer occurs prior to the beginning of treatment, or at the first definitive surgery. Clinical staging, which includes radiography and exam findings, takes place initially. Pathologic staging, which is obtained from surgical specimens, can be acquired during the course of surgical treatment. Patients then carry either the clinical stage or the pathologic stage for the duration of their illness.
2. Because the initial clinical or pathologic stage is carried for the duration of a patient's illness, patients with Stage I disease who later develop metastases still have Stage I disease -any given cancer is only staged once.
3. Specific criteria are revised periodically, but the principles of TNM classification are constant for all solid tumors:
-T describes the size or extent of local invasion of the primary tumor -N describes regional lymph node involvement -M describes metastatic disease -G describes the pathologic grade of the primary tumor The TNM classification translates to Stage groupings, generally 0-4. 4. Some cancers, including sarcomas, include G (grade) in the Stage Grouping.
5. Cancer stages are created to provide prognostic information and guide treatment decisions.
6. Leukemia, lymphoma, some pediatric malignancies, and a few rare adult malignancies use different staging systems that do not rely on TNM information.
7. Restaging, a term in common use for reassessing a patient's current disease state, is a misnomer.
8. The American College of Surgeons requires pretreatment staging on the chart of each patient. All patients can be staged clinically. Pathologic staging provides more accurate information and is the one most physicians use if available.
9. Staging systems are periodically revised and it is important to know which version was used.
Overview
The "stage" of a cancer is a short-hand way of describing the extent of cancer in a patient. Stage is based on macroscopic involvement of tissues by cancer. By contrast, the "grade" of a cancer is a 
Biopsies
As part of the staging process, fine needle aspirate (FNA) or core biopsies may be performed of the primary tumor, enlarged regional lymph node, or site of possible metastasis. Biopsies generally have a high specificity but poor sensitivity. This implies that a biopsy positive for malignant cells is diagnostic and adequate for pathologic staging of nodes or metastases. However, the absence of malignant cells in a biopsy sample is not sufficient to rule out cancer in patients with a high index of suspicion, and the suspicion is sufficient to include the site in clinical staging.
The presence of malignant cells informs the TNM staging process in several ways:
-pT: Biopsy is insufficient to define pathologic T Stage;
pathologic staging requires resection of the primary -pN: Confirms presence of malignant cells in regional lymph nodes -pM: Confirms presence of distant metastatic disease If biopsy is not possible or results are not available, staging can be done based solely on imaging and physical exam. In this case, the stage is annotated with the prefix "c" to indicate clinical staging without biopsy information.
T: Tumor
There are several different categories of primary tumor classification based mainly on the size or extent of local invasion of the tumor.
Typically the T is determined by imaging studies, although in the case of some palpable masses this can be supplemented by direct measurement.
For certain cancers, including breast, carcinoma in situ is staged Tis, and grouped as Stage 0. 
N: Node
The definition of a regional lymph node varies by the tumor location and local anatomy. N0 is used to indicate the lack of any suspicious lymph nodes on imaging and exam, or pathology.
If the patient has enlarged lymph nodes on exam or imaging, ideally these should be biopsied to determine if there is any malignancy present. If biopsy cannot be performed, is non-diagnostic, or is negative in the face of substantial clinical suspicion, the clinician may opt for the classification Nx. This indicates that node status cannot be assessed clinically. Often this Nx status is revised following surgical resection, although this may not be possible if the patient receives chemotherapy or radiation therapy prior to node dissection (neoadjuvant therapy).
Staging of Cancer
If regional lymph nodes are found to have malignant cells, the number and location of the involved nodes is designated with N1, N2, and N3 classifications. Table 2 illustrates the AJCC N classifications for breast and lung cancer. 
TNM to Staging
Once the TNM classification is determined, this can be used to determine the clinical or pathologic stage of disease. There are typically at least 32 different TNM classifications possible (T1-4, N0-3, M0-1), even without considering various modifiers and subclasses. This is an unwieldy number that is not necessary for high-level discussion of disease severity and potential treatment response.
Therefore the many different TNM categories are grouped into Stages I-IV. Typically metastatic disease (M1) is Stage IV, regardless of the T or N classification. Based on the AJCC Staging Manual, ,7 th edition, a simplified example is shown in Table 3 : Table 3. AJCC lung cancer staging   Lung Cancer N0  N1  N2  N3   T1  T1N0M0  T1N1M0  T1N2M0  T1N3M0   T2  T2N0M0  T2N1M0  T2N2M0  T2N3M0   T3  T3N0M0  T3N1M0  T3N2M0  T3N3M0   T4  T4N0M0  T4N1M0 T4N2M0 T4N3M0
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Lung Cancer: 
Pathology
If the tumor and/or regional nodes are removed surgically, more 
Leukemia, Brain Cancer, etc
Some malignancies are not easily described by the TNM system.
Due to their diffuse nature, leukemias are not staged. Accurate pathologic description of leukemias (e.g., acute vs. chronic, myeloid vs. lymphoid, etc.) is very important in determining prognosis and treatment options for patients. In contrast to leukemias, primary cancers of the brain rarely spread outside of the brain. T stage is relevant in brain tumors. It should be readily apparent that the N and M components of the TNM system are meaningless for a malignancy that does not spread away from its primary organ. Like leukemias, the pathologic description of brain tumors is critically important to predicting prognosis and guiding treatment options for patients.
Progression
A patient's tumor will retain the initial clinical or pathologic staging regardless of disease development. If the primary tumor progresses (T), develops nodal involvement (N) or metastasizes (M), the patient's disease stage does not change, but is noted that the disease has progressed along certain dimensions. The term restaging is heard very often when a reassessment of the current state of a patient's disease is needed, but is a misnomer because it confuses people.
Revisions of Staging Systems
Since the goal of the staging system is to provide prognostic information to the patient and to compare groups of patients with similar prognosis, the staging system for a given cancer may be revised over time based on a review of outcomes for a large number of patients. In addition, changes in technology, usually imaging technology, may lead to improvements in staging systems.
As imaging improves (for example as CT or PET scans become more available), suspicious nodes may be visualized, moving patients into a higher stage grouping than they would have been in based only on older imaging and physical examination. This group of patients will do better than expected for the new higher stage, but would have had the worst prognosis in the former, lower stage. CT-X-ray computed tomography, a series of X-rays that are digitally processed to produce a 3 dimensional map of the density of the body part being imaged. The patient receives a higher dose of radiation than is received in an X-ray.
Grade-A determination of how well or poorly differentiated cancer cells appear to be based on microscopic assessment of a tumor specimen MRI-Magnetic resonance imaging, a medical imaging technique wherein the patient is placed in a strong magnetic field. In such fields, hydrogen nuclei give different responses to low-energy radio frequencies according to the local chemical environment. From these responses, 3 dimensional maps of body tissue types are produced. MRI scans are not associated with radiation exposure and are useful in contrasting soft tissues.
Neoadjuvant-Administration of a therapy in preparation for a main treatment. Examples include hormone therapy, radiation therapy and chemotherapy, which may shrink the tumor and make the main treatment safer and/or more effective.
Pathologic staging-Obtained from surgical specimens PET Scan-Positron emission tomography, a medical imaging technique wherein positron-emitting tracer is incorporated into (usually) a glucose analog and injected into the body. The complex is taken up by the body tissues, with greater uptake in metabolically active areas. As positrons are emitted, they collide with electrons, and produce pairs of gamma ray photons moving in opposite directions, which are detected and localized. This forms a 3dimensional map of areas of maximal tracer uptake in the body.
TNM Staging System-A common staging system developed by the American Joint Committee on Cancer X ray-Photons with a shorter wavelength than ultraviolet light are created and passed through the tissues of interest. Dense objects absorb more of the photons, casting a shadow on the sensor on the other side of the body part.
